Gastric adenocarcinoma is the second leading cause of cancer death worldwide, following lung cancer. The five-year survival rate of advanced metastatic disease is low. Combination chemotherapy results in improvement in overall survival in comparison with single-agent treatment or supportive care (1,2). Limited progress has been made by adding targeted therapy to the treatment of gastric cancer. The only two targeted agents approved by the US Food and Drug Administration (FDA) are ramucirumab (3,4), a VEGF antibody, and trastuzumab (5), which is indicated only in tumors with amplified human epidermal growth factor receptor 2 (Her-2). Both drugs have a modest impact on overall survival.

中文翻译：

---

用于EBV阳性胃癌的PD-L1抗体，超越了PD-L1表达和微卫星不稳定性

胃腺癌是继肺癌之后全球第二大导致癌症死亡的主要原因。晚期转移性疾病的五年生存率很低。与单药治疗或支持治疗相比，联合化疗可提高总生存期（1,2）。通过在胃癌的治疗中增加靶向治疗取得了有限的进展。美国食品药品监督管理局（FDA）批准的仅有的两种靶向药物是雷莫西单抗（3,4），VEGF抗体和曲妥珠单抗（5），仅在扩增的人类表皮生长因子受体2（Her -2）。两种药物都对总体存活率产生适度的影响。